LEAP-2 increases whereas ghrelin decreases in obesity, and LEAP-2 is implicated in obesity-related disorders, including polycystic ovary syndrome and non-alcoholic fatty liver disease [363]. Here, LEAP2 is linked to metabolic dysfunction-associated steatotic liver disease.